EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
2.6.1.19 | (1R,4S)-4-amino-2-cyclopentene-1-carboxylic acid + 2-oxoglutarate |
analogue of 4-aminobutanoate, vigabatrin |
Sus scrofa |
? + L-glutamate |
- |
? |
2.6.1.19 | (4R)-4-amino-1-cyclopentene-1-carboxylic acid + 2-oxoglutarate |
analogue of 4-aminobutanoate, vigabatrin |
Sus scrofa |
4-oxo-1-cyclopentene1-carboxylic acid + L-glutamate |
- |
? |
2.6.1.19 | (R)-4-amino-3-fluorobutanoic acid |
- |
Sus scrofa |
4-aminobut-2-enoic acid + HF |
- |
? |
2.6.1.19 | (R,S)-4-amino-3-fluorobutanoic acid |
neither enantiomer is a substrate for transamination. The rate of elimination of HF from the (R)-enantiomer is at least 10 times greater than that for the (S)-enantiomer |
Sus scrofa |
4-aminobut-2-enoic acid + HF |
- |
? |
2.6.1.19 | (S)-4-amino-4,5-dihydro-2-thiophenecarboxylic acid + 2-oxoglutarate |
mechanism-based inactivator that partly undergoes inactivation |
Sus scrofa |
4-oxo-4,5-dihydro-2-thiophenecarboxylic acid + L-glutamate |
- |
? |
2.6.1.19 | 1H-tetrazole-5-butanamine + 2-oxoglutarate |
- |
Sus scrofa |
(1H-tetrazol-5-yl)-butyraldehyde + L-glutamate |
- |
? |
2.6.1.19 | 1H-tetrazole-5-ethanamine + 2-oxoglutarate |
- |
Sus scrofa |
(1H-tetrazol-5-yl)-acetaldehyd + L-glutamate |
- |
? |
2.6.1.19 | 1H-tetrazole-5-propanamine + 2-oxoglutarate |
- |
Sus scrofa |
(1H-tetrazol-5-yl)-propionaldehyde + L-glutamate |
- |
? |
2.6.1.19 | 3-(aminomethyl)benzoic acid + 2-oxoglutarate |
3.4% of the activity with 4-aminobutanoate |
Sus scrofa |
3-(iminomethyl)benzoic acid + L-glutamate |
- |
? |
2.6.1.19 | 3-aminoisobutanoate + 2-oxoglutarate |
- |
Mus musculus |
L-glutamate + 3-oxoisobutanoate |
- |
r |